As previously reported, Oppenheimer upgraded Avalo Therapeutics (AVTX) to Outperform from Perform with a $35 price target on the firm’s optimism that AVTX-009 offers a best-in-class profile in the competitive hidradenitis suppurativa space. In late March, Avalo announced a deal to acquire privately held AlmataBio and a concomitant private placement financing of up to $185M. The anti-IL-1beta antibody, now called AVTX-009, to be gained in the combination was originally developed by Eli Lilly (LLY), Oppenheimer notes. As the company readies ‘009 for Phase 2 development in hidradenitis suppurativa, the firm is constructive on this new asset and its potential. Although topline data are not expected until 2026, advancement of ‘009 into evaluation for another inflammatory indication, potentially ulcerative colitis, is on the table and could provide interim news flow, the firm adds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVTX:
- Avalo Therapeutics appoints Kantoff, Goldman, Truex as independent directors
- Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
- Avalo Reports 2023 Financial Results and Provides Business Updates
- Avalo Therapeutics’ Strategic Expansion and Leadership Revamp
- Avalo Therapeutics up 227% afterhours at $15.60 after announcing AlmataBio deal